Clene appoints Dr. Vallerie McLaughlin as independent director, effective August 5, 2021

Clene Inc.

Appointed Vallerie V. McLaughlin, M.D. as Class III director and member of Nominating and Corporate Governance Committee.
Received option award for 45,000 shares at $9.37 exercise price, vesting in 36 monthly installments.
Also received immediate options valued at $11,000 (Board $10,000 + committee $1,000) at $9.37 exercise price.
Dr. McLaughlin is professor at University of Michigan, expert in pulmonary hypertension rare disease trials.
She becomes the seventh independent director on the seven-member board.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Vallerie V. McLaughlin, M.D.

Director

CLNN · Clene Inc.

Effective: 2021-08-05
Filed: August 9, 2021, 7:59 PM ET

On August 5, 2021, the Board of Directors (the “Board”) of Clene Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Vallerie V. McLaughlin, M.D. as a member of the Board, effective August 5, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vallerie V. McLaughlin, M.D. was appointed as Director at Clene Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 5, 2021, the Board of Directors (the “Board”) of Clene Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Vallerie V. McLaughlin, M.D. as a member of the Board, effective August 5, 2021.

View on SEC.gov

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001213900-21-041062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.